期刊文献+

吉非替尼与厄洛替尼二线治疗EGFR基因敏感突变晚期NSCLC患者的疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨吉非替尼与厄洛替尼二线治疗EGFR基因敏感突变非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床疗效和安全性。方法选择我院2013年3月至2015年2月收治的一线化疗失败的EGFR基因敏感突变晚期NSCLC患者50例,按随机数字表法平均分为两组,一组接受吉非替尼(吉非替尼组)250 mg/d治疗,另一组接受厄洛替尼(厄洛替尼组)150 mg/d治疗,观察无进展生存时间(PFS)、总有效率(ORR)、疾病控制率(DCR)和药物的毒副反应。结果吉非替尼组和厄洛替尼组的中位PFS、ORR、DCR分别为(6.5±1.2)个月、60%、92%和(7.2±0.9)个月、56%、88%,差异均无统计学意义(P>0.05)。吉非替尼组和厄洛替尼组的毒副反应发生率分别为32%和60%,差异具有统计学意义(P<0.05)。结论吉非替尼和厄洛替尼均能有效地二线治疗EGFR基因敏感突变晚期NSCLC患者,疗效相当,但吉非替尼治疗的毒副反应发生率明显低于厄洛替尼。
出处 《中国癌症防治杂志》 CAS 2016年第3期171-173,共3页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金 东莞市医疗卫生科技计划一般项目(201310515000310)
  • 相关文献

参考文献11

  • 1Jenaal A, Thomas A, Murray T,et al.Cancer statistics,2002 [J ].CA Cancer J Clin,2002,52( 1 ) :23-47.
  • 2Lee DH,Park K,Kim JH,et al.Random-ized phase Ⅲtrial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy[J].Clin Cancer Res, 2010,16(4) : 1307-1314.
  • 3Fukuoka M,Wu YL,Thongprasert S, et al.Biomarker analyses and final overall survival results ffoma phase Ⅲ, randomized, open-label, firstline study of gefitinib venus carboplatin/paclitaxel in clinically se lected patients with advanced non-small-cell lung cancer in Asia (IPASS) [J].J Clin Oncol,2011,29(21 ) :2866-2874.
  • 4Zhou C,Wu YL,Chen G,et al.Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802 ) : a muhicentre,open-label,randomised,phase 3 study[J ].Lancet Oncol, 2011, 12(8):735-742.
  • 5Kim S,Uhm JE,Lee J,et al. Randomized phase Ⅱ study of gefitinib versus erlotinib in patients with advaneed non-small eell lung eaneer who failed previous chemotherapy[J].Lung Cancer,2012,75 (1): 82-88.
  • 6Kim ST,Lee J,Kim JH,et al. Comparison of gefitinib versus erlotinib in patients with non small cell lung cancer who failed previous chemotherapy[J].Cancer, 2010,116(12) : 3025-3033.
  • 7Rosell R,Moran T,Querah C,et al. Screening for epidermal growthfactor receptor mutations in lung cancer[ J ].N Engl J Med, 2009,361 (10) : 958-967.
  • 8张琴,周韶璋,黄明月,戴辉,葛莲英.多西他赛或表皮生长因子受体酪氨酸激酶抑制剂二线治疗晚期非小细胞肺癌的临床观察[J].中国癌症防治杂志,2015,7(2):94-99. 被引量:5
  • 9Yamada K, Aono H, Hosomi Y,ct al.A prospective, muhicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy : Thoracic Oncology Research Group 0911 [ J ].Eur J Cancer, 2015,51 ( 14 ) : 1904-1910.
  • 10Huang Y,Zhang L,Shi Y,et al.Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study[J].Jpn J Clin Oncol, 2015,45(6) : 569-575.

二级参考文献32

  • 1Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-917.
  • 2Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CA Cancer J Clin, 2012, 62(1): 10-29.
  • 3Herbst RS, Heymach JV, Lippman SM. Lung cancer[J]. N Engl JMed, 2008, 360: 1367-80.
  • 4Feld R, Sridhar SS, Shepherd FA, et al. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: A systematic review[J]. J Thorac Oncol, 2006, 1(4): 367-76.
  • 5Figlin RA, Crowley JJ, Jacobs EL, et al. Evaluation of cisplatin, Carboplatin, and etoposide in metastatic non-small-cell lung carcinoma: A phase II study of the southwest Oncology Group [J]. Cancer, 1996, 78(5): 998-1003.
  • 6Vanderwalde A, Pal SK, Reckamp KL. Management of non-small-cell lung cancer in the older adultIJ. Maturitas, 2011, 68 (4): 311-21.
  • 7Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer[J]. Proc Am Thorac Soc, 2009, 6 (2): 233-41.
  • 8Fukuoka M, Wu ; Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)[J]. J Clin oncol, 2011, 29(21): 2866-74.
  • 9Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation- positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study [ J]. Lancet Oncol, 2011, 12(8): 735-42.
  • 10Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer[J]. N Engl J Med, 2009, 361(10): U38-958.

共引文献41

同被引文献27

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部